Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development
Epilepsy is a serious neurological disorder that affects around 50 million people worldwide. Almost 30% of epileptic patients suffer from pharmacoresistance, which is associated with social isolation, dependent behaviour, low marriage rates, unemployment, psychological issues and reduced quality of...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2010-07-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1424-8247/3/7/2090/ |
| _version_ | 1811286947521363968 |
|---|---|
| author | Abdul Wahab |
| author_facet | Abdul Wahab |
| author_sort | Abdul Wahab |
| collection | DOAJ |
| description | Epilepsy is a serious neurological disorder that affects around 50 million people worldwide. Almost 30% of epileptic patients suffer from pharmacoresistance, which is associated with social isolation, dependent behaviour, low marriage rates, unemployment, psychological issues and reduced quality of life. Currently available antiepileptic drugs have a limited efficacy, and their negative properties limit their use and cause difficulties in patient management. Antiepileptic drugs can provide only symptomatic relief as these drugs suppress seizures but do not have ability to cure epileptogenesis. The long term use of antiepileptic drugs is limited due to their adverse effects, withdrawal symptoms, deleterious interactions with other drugs and economic burden, especially in developing countries. Furthermore, some of the available antiepileptic drugs may even potentiate certain type of seizures. Several in vivo and in vitro animal models have been proposed and many new antiepileptic drugs have been marketed recently, but large numbers of patients are still pharmacoresistant. This review will highlight the difficulties in treatment and management of epilepsy and the limitations of available antiepileptic drugs and animal seizure models. |
| first_indexed | 2024-04-13T03:08:59Z |
| format | Article |
| id | doaj.art-a297ac8c73564c5fa0107378f9442b75 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-04-13T03:08:59Z |
| publishDate | 2010-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-a297ac8c73564c5fa0107378f9442b752022-12-22T03:05:08ZengMDPI AGPharmaceuticals1424-82472010-07-01372090211010.3390/ph3072090Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug DevelopmentAbdul WahabEpilepsy is a serious neurological disorder that affects around 50 million people worldwide. Almost 30% of epileptic patients suffer from pharmacoresistance, which is associated with social isolation, dependent behaviour, low marriage rates, unemployment, psychological issues and reduced quality of life. Currently available antiepileptic drugs have a limited efficacy, and their negative properties limit their use and cause difficulties in patient management. Antiepileptic drugs can provide only symptomatic relief as these drugs suppress seizures but do not have ability to cure epileptogenesis. The long term use of antiepileptic drugs is limited due to their adverse effects, withdrawal symptoms, deleterious interactions with other drugs and economic burden, especially in developing countries. Furthermore, some of the available antiepileptic drugs may even potentiate certain type of seizures. Several in vivo and in vitro animal models have been proposed and many new antiepileptic drugs have been marketed recently, but large numbers of patients are still pharmacoresistant. This review will highlight the difficulties in treatment and management of epilepsy and the limitations of available antiepileptic drugs and animal seizure models.http://www.mdpi.com/1424-8247/3/7/2090/antiepilepticanticonvulsantseizurepharmacoresistancerefractory seizures |
| spellingShingle | Abdul Wahab Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development Pharmaceuticals antiepileptic anticonvulsant seizure pharmacoresistance refractory seizures |
| title | Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development |
| title_full | Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development |
| title_fullStr | Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development |
| title_full_unstemmed | Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development |
| title_short | Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development |
| title_sort | difficulties in treatment and management of epilepsy and challenges in new drug development |
| topic | antiepileptic anticonvulsant seizure pharmacoresistance refractory seizures |
| url | http://www.mdpi.com/1424-8247/3/7/2090/ |
| work_keys_str_mv | AT abdulwahab difficultiesintreatmentandmanagementofepilepsyandchallengesinnewdrugdevelopment |